First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
| Image |  |
|---|---|
| Description | scientific article published on 01 October 2019 |
| Author/s |
author: Jean-François Dufour Debashis Sarker Su-Pin Choo Lynn G Feun Antoine Hollebecque Nicolas Stransky |
| Publication date | October 1, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |